Top Oncolytic Virus Companies

Our mission is to accelerate development of novel therapeutics by providing researchers with high-quality products and services for all stages of research. We are passionate about diving deep into the science to discover novel and innovative solutions for next-generation therapies. We are all about working with sponsors to help them overcome the challenges of their research. We provide a wide range of services to support early research and development through the clinical phase. We provide custom biodistribution, immunogenicity, pharmacokinetics, and biomarker assay services to support discovery through clinical phases. Experts in virology, immuno-oncology, cell and vector engineering, and assay development, our vision is to be a leader in research services and laboratory assays. This scientific approach to each project is what allows us to deliver excellence in contract research, custom products, and virus assays to support development of oncolytic virus therapies, gene and cell therapies, regenerative medicines, and vaccines. What makes Imanis stand out is our diverse scientific team of experts in virology, immuno-oncology, molecular biology, and assay development.

Our mission is to deliver the highest quality products, to provide dedicated technical support to our customers worldwide, and to satisfy customers' specific needs with customized solutions. We are fully engaged in developing unique technologies to facilitate the investigation of microbial research. Our promise to you: Guaranteed product quality, expert customer support. As a scientists-founded and scientists-driven leading biotechnological company, Creative Biogene focuses on developing high quality products and services, as well as proprietary technology to support the research in the field of basic life sciences research, biomedical development, industrial synthetic application and preclinical drug discovery. With the support of an innovative portfolio of products and a custom-service-centered business model, Creative Biogene is gradually recognized by worldwide customers as a biotech institution specializing in fundamental life sciences research. At Creative Biogene, Our in-house experts continually work on developing tools and innovative solutions for the bioresearch community. Creative Biogene provides customized molecular biology reagents and professional technical services to customers in the life science research field. Kit is a collection of reagents or devices that can perform a specific biological experiment.

Our vision: Affordable, best-in-class cancer treatments with fewer side effects for an improved quality-of-life under treatment. CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. CanVirex and Heidelberg University Hospital have signed a strategic collaboration agreement for the research and clinical development of measles-vectored therapeutics. CanVirex has also forged strategic collaborations with key industry partners for GMP manufacturing and commercialization of our products. CanVirex’s measles vector-based platform represents a highly promising technology for cancer immunotherapy and vaccine development against infectious diseases. CanVirex AG operates out of its headquarter in Basel, Switzerland. The Heidelberg University Hospital offers a unique infrastructure for swift clinical translation of our most promising drug candidates. The translational program, supported by CanVirex, routinizes testing of molecular signatures and predictive biomarkers.

Therapoid' free Therapoid open science platform enables responsible and socioeconomically diverse researchers and students around the world to collaborate. All the sciences impact animal, human, and global health outcomes. This includes the impacts brought about by climate change. Our interdisciplinary approach supports achieving positive health outcomes for everyone. Therapoid enables scientists and students to share research easily, while it also opens a path to develop untapped technologies.

Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer. Off-the-shelf allogeneic cell therapy has significant advantages and is the next frontier in cancer treatment. Tessa is developing a unique and potentially transformational allogeneic CD30-CAR EBVST platform capable of targeting a broad range of cancers. This platform is based on decades-long research and development on unique properties of Virus Specific T-cells (VSTs) by our Scientific Co-Founder, Dr. Malcolm Brenner, and his team at Baylor College of Medicine.

The story of Rigvir Group was started by professor Aina Muceniece, a pioneer scientist who looked into the future and unlocked the potential of oncolytic virotherapy for cancer patients. Rigvir Group wishes success and rapid expansion of the good virus around the world. Rigvir has once again received international confirmation that it is non-toxic, has high tolerability and does not induce any severe adverse event even at increased doses. Henceforth, Rigvir virus is going to be developed also in the non-medical field which could provide preventive help to people with high cancer-risks or scientifically proven cancer presence in the body even before cancer can be diagnosed. Rigvir group has made a decision to offer a fundamentally new approach to cancer prevention. With this deal, the Rigvir group has further distanced itself from the commercialisation of the medicine and approached Biotech format with a focus on product development and further licensing. Rigvir's new API (Active pharmaceutical ingredient) center of manufacturing has received GMP (Good Manufacturing Practice) compliance certification for the production of Rigvir virus ECHO-7. We are committed to prove, that the cancer treatment can be safe, effective and harmless.

We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations. We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897. More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world. OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world. OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We produce a wide range of viral vectors: Vaccinia, MVA, Adeno, Measles, ORF, Arenavirus, AAV and others. We are grounded in the Mérieux family’s legacy of biology and vaccine expertise since 1897.

Through an unwavering dedication to customer service and emphasis on innovative technologies, Nitta Gelatin has expanded its footprint, with 15 facilities across 6 countries. Utilizing our technical expertise and over a century of know-how, we provide our customers with leading-edge R&D, exceptional technical service, and consistently high-quality products. In 2006, Nitta Gelatin opened the doors to its state-of-the-art gelatin and collagen peptide production facility in Fayetteville, North Carolina. Nitta Gelatin celebrates over 100 years as a trusted producer of gelatin and collagen ingredients for the food, dietary supplement, and pharmaceutical markets. Founded in Osaka, Japan, Nitta gelatin has grown into a global supplier, with 15 facilities across 6 countries. In keeping with our pioneering spirit, Nitta Gelatin continually strives to develop new products, functions, and applications for the future. Rapid-set gelatin designed for use with complex formulations and starchless gummy manufacturing. Exceptionally high biocompatibility, viral inactivation, and endotoxin reduction, yielding collagen and gelatin products for the biomedical marketplace.

Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs. Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, we work collaboratively to rapidly advance programs from target through to preclinical selection and beyond. This integration of capabilities allows a collaborative environment, enabling enhanced efficiency and productivity. We aim to provide outstanding services to our existing partners and to the broader discovery community. Delivering our partners preclinical discoveries through world class capabilities, directed by teams with a reputation for collaboration and scientific excellence. WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic. Our world-class discovery platform is backed by nearly 3000 scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities. From small molecules, oligonucleotides, and peptides to antibodies, cell, and gene therapies, our state-of-the-art services, fast turnaround times, and quick study launches meet the diverse needs of our clients. Expertise in synthetic and medicinal chemistry, biology, DMPK and program management for drug discovery.